证券代码：002019 证券简称：亿帆医药 公告编号：2025-048 亿帆医药股份有限公司 独立董事候选人声明与承诺 声明人刘梅娟作为亿帆医药股份有限公司第九届董事会独立董事候选人， 已充分了解并同意由提名人亿帆医药股份有限公司董事会提名为亿帆医药股 份有限公司（以下简称"该公司"）第九届董事会独立董事候选人。现公开声 明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关 法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过亿帆医药股份有限公司第九届董事会提名委员会或者独 立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情形的密切关系。 是 □否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 是 □否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 是 □否 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 是 □否 ...

2025-049 证券代码：002019 证券简称：亿帆医药 公告编号： 亿帆医药股份有限公司 独立董事提名人声明与承诺 提名人亿帆医药股份有限公司董事会现就提名曾玉红为亿帆医药股份有限 公司第九届董事会独立董事候选人发表公开声明。被提名人已书面同意作为亿 帆医药股份有限公司第九届董事会独立董事候选人（参见该独立董事候选人声 明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全 部兼职、有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符 合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对 独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过亿帆医药股份有限公司第九届董事会提名委员会或 者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或者其他可 能影响独立履职情形的密切关系。 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所业务规则规定的独立董事任职资格和条件。 是 □否 如否，请详细说明： 四、被提名人符合公司章程规定的独立董事任职条件。 是 □否 如否，请详细说明： 是 □否 如否，请详细说明： ...

关于调整2022年员工持股计划管理委员会成员的公告 证券代码：002019 证券简称：亿帆医药 公告编号：2025- 051 亿帆医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 周秦先生未在公司控股股东或实际控制人单位担任职务，不是公司 5%以上 股东、实际控制人、董事、监事、高级管理人员，与前述主体不存在关联关系。 特此公告。 亿帆医药股份有限公司董事会 亿帆医药股份有限公司（以下简称"公司"）于 2025 年 8 月 14 日以现场加 通讯表决的方式召开公司 2022 年员工持股计划第三次持有人会议，审议通过了 《关于调整 2022 年员工持股计划管理委员会委员的议案》。由于公司 2022 年员 工持股计划管理委员会委员之一钱莉苹女士因职务调整，申请辞去管理委员会委 员职务，为更好地保障员工持股计划的整体利益，决定选举周秦先生为公司 2022 年员工持股计划管理委员会委员，与第一次持有人会议、第二次持有人会议选举 产生的李佳先生、李蕾女士共同组成公司 2022 年员工持股计划管理委员会，任 期与 2022 年员工持股计划存续期保持一致。 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-047 亿帆医药股份有限公司 独立董事候选人声明与承诺 声明人曾玉红作为亿帆医药股份有限公司第九届董事会独立董事候选人， 已充分了解并同意由提名人亿帆医药股份有限公司董事会提名为亿帆医药股 份有限公司（以下简称"该公司"）第九届董事会独立董事候选人。现公开声 明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关 法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过亿帆医药股份有限公司第九届董事会提名委员会或者独 立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情形的密切关系。 是 □否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 是 □否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 是 □否 如否，请详细说明： 是 □否 四、本人符合该公司章程规定的独立董事任职条件。 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-052 关于董事会换届选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）第八届董事会任期已届满，根 据《公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律 监管指引第1号—主板上市公司规范运作》等相关法律法规、规范性文件及《公 司章程》的有关规定，经公司第八届董事会提名委员会资格审查，公司于2025 年8月13日召开第八届董事会第十八次会议，审议通过了《关于董事会换届选举 非独立董事的议案》《关于董事会换届选举独立董事的议案》，现将具体情况公 告如下： 一、董事会换届选举情况 根据《公司法》和《公司章程》的相关规定，公司第九届董事会由6名董事 组成，其中非独立董事3名，独立董事2名，职工代表董事1名。 经公司第八届董事会提名委员会资格审查，第八届董事会第十八次会议审议， 董事会同意提名程先锋先生、林行先生、冯德崎先生为公司第九届董事会非独立 董事候选人；提名曾玉红女士、刘梅娟女士为公司第九届董事会独立董事候选人。 上述简历详见下文附 ...

亿帆医药股份有限公司 《公司章程》修正案 | 修订前 | 修订后 | | --- | --- | | 第一条 为维护公司、股东和债权人的合法权益，规范 | | | 公司的组织和行为，根据《中华人民共和国公司法》（以 | 第一条 为维护公司、股东、职工和债权人的合法权益，规 | | | 范公司的组织和行为，根据《中华人民共和国公司法》（以 | | 下简称《公司法》）、《中华人民共和国证券法》（以 | 下简称《公司法》）、《中华人民共和国证券法》（以下 | | 下简称《证券法》）和其他有关规定，制订本章程。 | | | | 简称《证券法》）和其他有关规定，制定本章程。 | | 第二条 公司系依照《公司法》和其他有关规定成立的 | 第二条 公司系依照《公司法》和其他有关规定成立的股 | | 股份有限公司（以下简称"公司"）。 | | | | 份有限公司（以下简称"公司"）。 | | 公司经浙江省人民政府授权的部门浙江省人民政府企 | 公司经浙江省人民政府授权的部门浙江省人民政府企业 | | 业上市工作领导小组浙上市［2000］37 号文批准，以发 | | | | 上市工作领导小组浙上市［2000］37 号文批准，以 ...

证券代码：002019 股票简称：亿帆医药 公告编号：2025-053 亿帆医药股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）第八届董事会第十八次会议决 定于2025年9月5日（星期五）召开2025年第二次临时股东会。 通过深圳证券交易所互联网投票系统进行网络投票，开始时间为2025年9月5 日上午9:15至下午15:00。 5、会议召开方式：本次会议采取现场表决和网络投票相结合的方式召开。 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 2、股东会召集人：公司董事会 2025年8月13日召开的第八届董事会第十八次会议以8票同意、0票反对、0 票弃权的结果，审议通过了《关于召开2025年第二次临时股东会的议案》。 3、会议召开的合法、合规性 本次股东会的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 4、会议召开的日期、时间 现场会议召开的时间：2025 年 9 月 5 日下午 1:30 起 网络投票的时间：202 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-045 亿帆医药股份有限公司 第八届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 《第八届监事会第十五次会议决议》 特此公告。 亿帆医药股份有限公司监事会 2025年8月15日 亿帆医药股份有限公司（以下简称"公司"）第八届监事会第十五次会议于 2025 年 8 月 1 日以邮件的方式发出通知，于 2025 年 8 月 13 日以现场的方式在 公司一楼会议室召开。会议由监事会主席许国汉先生主持，会议应参加表决的监 事 3 人，实际参加表决的监事 3 人。会议的召开符合《公司法》和《公司章程》 的相关规定，会议合法有效。 二、监事会会议审议情况 经全体监事认真审议，会议以投票表决的方式形成以下决议： （一）会议以 3 票同意、0 票反对、0 票弃权的结果，审议通过了《公司 2025 年半年度报告及其摘要》 经审核，监事会认为：公司董事会编制和审核《2025 年半年度报告》和《2025 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定， ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) This section includes critical disclaimers from management, the report's structural overview, a list of reference documents, and definitions of key terms and entities [Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) Management assures report accuracy, declares no dividends or capital transfers, and outlines key risks such as international trade, R&D, and goodwill impairment - The company's board of directors, supervisory board, and senior management guarantee the **truthfulness, accuracy, and completeness** of the semi-annual report, free from false records, misleading statements, or major omissions, and assume individual and joint legal responsibility[4](index=4&type=chunk) - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital[5](index=5&type=chunk) - No exceptionally significant risks substantially impacting the company's operations occurred during the reporting period, but detailed discussions cover **international trade risks, R&D underperformance risks, goodwill impairment risks, exchange rate fluctuation risks, international operation risks, and safety and environmental protection risks**[4](index=4&type=chunk) [Table of Contents](index=3&type=section&id=%E7%9B%AE%E5%BD%95) This section lists the report's nine main chapters and their starting page numbers, providing an overall structural overview for investors - The report comprises **nine main chapters**, covering important notices, company profile, management discussion and analysis, corporate governance, significant events, share changes, bond information, financial reports, and other submitted data[7](index=7&type=chunk) [List of Reference Documents](index=4&type=section&id=%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) This section lists all publicly disclosed company documents, original announcements, financial statements, and the original semi-annual report text as reference materials for the reporting period - Reference documents include signed and sealed financial statements, all publicly disclosed original company documents and announcements, the original semi-annual report text signed by the legal representative, and other reference materials[9](index=9&type=chunk) [Definitions](index=5&type=section&id=%E9%87%8A%E4%B9%89) This section defines common terms, the company and its main subsidiaries, R&D products (e.g., F-627, F-652), and relevant regulatory bodies (e.g., NMPA, FDA, EMA) to ensure clear understanding of the report content - The report defines abbreviations for the **Company, Yifan Pharmaceutical, and its main subsidiaries** (e.g., Yifan Bio, Hefei Yifan, Yiyi Bio)[10](index=10&type=chunk)[11](index=11&type=chunk) - **F-627** refers to Epegfilgrastim Injection (Yilishu®/Ryzneuta®), and **F-652** refers to Recombinant Human Interleukin-22-Fc Fusion Protein, both being self-developed R&D products of the company[11](index=11&type=chunk) - **NMPA, FDA, and EMA** refer to the National Medical Products Administration, the U.S. Food and Drug Administration, and the European Medicines Agency, respectively[11](index=11&type=chunk) [Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides an overview of the company's basic information and presents key financial data and performance indicators for the reporting period [Company Profile](index=7&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) Yifan Pharmaceutical Co., Ltd. (stock code: 002019) is listed on the Shenzhen Stock Exchange, with Cheng Xianfeng as its legal representative, and contact information remained unchanged during the reporting period Company Basic Information | Metric | Content | | :--- | :--- | | Stock Abbreviation | Yifan Pharmaceutical | | Stock Code | 002019 | | Listing Exchange | Shenzhen Stock Exchange | | Chinese Name | Yifan Pharmaceutical Co., Ltd. | | Legal Representative | Cheng Xianfeng | - The company's registered address, office address, website, email, and information disclosure locations remained unchanged during the reporting period, as detailed in the 2024 annual report[15](index=15&type=chunk)[16](index=16&type=chunk) [Key Accounting Data and Financial Indicators](index=8&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In H1 2025, operating revenue slightly increased by 0.11% YoY, net profit attributable to shareholders grew by 19.91%, and non-recurring net profit increased by 32.21%, driven by higher innovative drug revenue and increased foreign exchange gains, with operating cash flow surging by 98.99% 2025 Semi-Annual Key Financial Data | Metric | Current Period (RMB) | Prior Period (RMB) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 2,635,110,083.18 | 2,632,089,783.35 | 0.11% | | Net Profit Attributable to Shareholders of Listed Company | 303,651,052.46 | 253,226,615.60 | 19.91% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items) | 237,210,048.08 | 179,419,522.02 | 32.21% | | Net Cash Flow from Operating Activities | 286,097,071.23 | 143,774,218.95 | 98.99% | | Basic Earnings Per Share (RMB/share) | 0.25 | 0.21 | 19.05% | | Diluted Earnings Per Share (RMB/share) | 0.25 | 0.21 | 19.05% | | Weighted Average Return on Net Assets | 3.49% | 2.96% | 0.53% | | **Period-end Indicators** | **Current Period-end (RMB)** | **Prior Year-end (RMB)** | **Change from Prior Year-end** | | Total Assets | 12,674,139,895.70 | 12,285,788,088.75 | 3.16% | | Net Assets Attributable to Shareholders of Listed Company | 8,771,392,564.72 | 8,521,867,867.56 | 2.93% | - Operating revenue increased by **0.11%**, primarily due to a significant increase in revenue from innovative and self-developed drugs, partially offset by a decrease in volume and price of some proprietary pharmaceutical products, and reduced revenue from vitamin products and pharmaceutical promotion services[18](index=18&type=chunk) - Net profit attributable to shareholders of the listed company (excluding non-recurring items) increased by **32.21%**, mainly driven by higher gross profit from high-value-added innovative and self-developed drugs, increased foreign exchange gains from financial expenses, and reduced credit impairment losses[18](index=18&type=chunk) - Net cash flow from operating activities increased by **98.99%**, primarily because the increase in cash received from sales of goods and provision of services outpaced the increase in cash paid for purchases of goods and acceptance of services[19](index=19&type=chunk) [Non-recurring Gains and Losses and Amounts](index=9&type=section&id=%E5%85%AD%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) During the reporting period, the company's total non-recurring gains and losses amounted to RMB 66,441,004.38, mainly comprising disposal gains/losses of non-current assets, government grants, fair value changes of financial assets/liabilities, and other non-operating income 2025 Semi-Annual Non-recurring Gains and Losses | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | Disposal gains/losses of non-current assets | 3,389,221.12 | Primarily net gains from disposal of intangible assets during the reporting period. | | Government grants recognized in current profit/loss (excluding those with continuous impact) | 64,177,846.31 | Primarily government grants received during the reporting period. | | Fair value changes and disposal gains/losses of financial assets and liabilities | 44,413.44 | Due to revaluation of foreign exchange derivatives at period-end and gains from matured time deposits. | | Other non-operating income and expenses | 1,847,214.24 | | | Less: Income tax impact | 2,565,065.42 | | | Impact on minority interests (after tax) | 452,625.31 | | | **Total** | **66,441,004.38** | | - Some government grants recognized in current profit/loss (**RMB 5,145,150.23**) were classified as recurring gains/losses because they are closely related to the company's normal operations, comply with national policies, are enjoyed according to established standards, and have a continuous impact on the company's profit and loss[24](index=24&type=chunk) [Management Discussion and Analysis](index=10&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section provides a comprehensive analysis of the company's main business, core competitiveness, financial performance, investment activities, and risk management strategies during the reporting period [Main Business Activities During the Reporting Period](index=10&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company's main business involves R&D, production, sales of pharmaceutical products (biologics, chemical drugs, traditional Chinese medicines), vitamins, and polymer materials, along with drug promotion services; innovative drug sales revenue grew by 169.57%, while vitamin products faced competitive pressure - The company primarily engages in the R&D, production, sales, and promotion services of **pharmaceutical products** (biologics, chemical drugs, traditional Chinese medicines), **vitamins, and polymer materials**, operating within the pharmaceutical manufacturing industry[26](index=26&type=chunk) - The pharmaceutical industry is undergoing deep adjustments and innovation breakthroughs, with traditional generic drugs facing pressure and innovative drugs experiencing explosive growth; in H1 2025, pharmaceutical manufacturing operating revenue decreased by **1.2%** and total profit decreased by **2.8%** year-on-year[28](index=28&type=chunk)[29](index=29&type=chunk) - Vitamin B5 and its precursor products hold a **high global market share** and a leading position, but currently face severe supply-demand imbalance and industry reshuffling[32](index=32&type=chunk)[37](index=37&type=chunk) - The company is one of the few Chinese enterprises to have obtained marketing approval from drug regulatory agencies in China, the U.S., EU, and Brazil for its **innovative biological products**, possessing a global pharmaceutical marketing and promotion network[34](index=34&type=chunk) - In H1 2025, proprietary (including imported) pharmaceutical operating revenue increased by **7.22%** year-on-year, and innovative drug sales revenue grew by **169.57%**, serving as the core driver for a significant increase in non-recurring net profit margin[38](index=38&type=chunk) [Company's Main Business](index=10&type=subsection&id=%EF%BC%88%E4%B8%80%EF%BC%89%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company's main business covers biologics, chemical drugs, traditional Chinese medicines, and vitamin products, with biologics like F-627 (Yilishu®) and recombinant human insulin sold globally, alongside various chemical and traditional Chinese medicines, and leading global sales of Vitamin B5 series products Main Product List | Product Category | Product Name | Sales Region | Indication/Description | | :--- | :--- | :--- | :--- | | Biologic | Epegfilgrastim Injection (F-627) | Global Sales | Reduces incidence of infection in febrile neutropenia caused by chemotherapy | | Biologic | Recombinant Human Insulin Injection | Global Sales | Regulates glucose metabolism, lowers blood sugar | | Chemical Drug | Capecitabine Tablets (Xeloda®) | Domestic Sales | Advanced or metastatic gastric cancer, colorectal cancer, breast cancer | | Chemical Drug | Sodium Hyaluronate Cross-linked with Butanediol Diglycidyl Ether Injection (Yinikang) | Domestic Sales | Knee osteoarthritis | | Traditional Chinese Medicine | Xiao'er Qingqiao Granules | Domestic Sales | Wind-heat tonsillitis, fever, sore throat, etc. | | Vitamin | Vitamin B5 and its precursor | Global Sales | Precursor to Coenzyme A, involved in metabolism, feed/food additive | [Industry Development Stage and Company's Industry Position](index=11&type=subsection&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E7%9A%84%E5%8F%91%E5%B1%95%E9%98%B6%E6%AE%B5%E3%80%81%E5%91%A8%E6%9C%9F%E6%80%A7%E7%89%B9%E7%82%B9%E4%BB%A5%E5%8F%8A%E5%85%AC%E5%8F%B8%E6%89%80%E5%A4%84%E7%9A%84%E8%A1%8C%E4%B8%9A%E5%9C%B0%E4%BD%8D) The pharmaceutical industry is in a phase of deep adjustment and innovation, with significant growth in innovative drugs, while the vitamin sector faces supply-demand imbalances; the company holds a prominent position in biologics, small molecules, traditional Chinese medicines, and synthetic biology, particularly in innovative biologics and internationalization - The pharmaceutical industry has entered a phase of deep adjustment and innovation breakthroughs, with traditional generic drugs facing pressure and innovative drugs experiencing explosive growth; the industry as a whole exhibits weak cyclicality and strong defensive characteristics[28](index=28&type=chunk)[31](index=31&type=chunk) - The vitamin industry faces severe supply-demand imbalance and reshuffling, but the company's **Vitamin B5 products** maintain a leading position in the segmented market[32](index=32&type=chunk) - The company has established a full lifecycle system for macromolecular drugs, from new drug discovery to commercial production, and has successfully launched its first innovative biologic, **Yilishu**, in **34 countries** including China, the U.S., EU, and Brazil[34](index=34&type=chunk)[35](index=35&type=chunk) - In the small molecule (chemical drug) sector, the company focuses on a differentiated product chain of 'small, sharp, and special' products, possesses an internationally aligned high-standard production quality management system, and is one of the few domestic enterprises with an integrated international R&D, production, and sales layout for pharmaceuticals[35](index=35&type=chunk) - The company owns **13 exclusive traditional Chinese medicine products** covered by medical insurance, including Baixuekang (Compound Huangdai Tablets®), an effective drug for treating acute promyelocytic leukemia, which is also listed on the **WHO Model List of Essential Medicines**[36](index=36&type=chunk)[37](index=37&type=chunk) [Key Performance Drivers](index=15&type=subsection&id=%EF%BC%88%E4%B8%89%EF%BC%89%E4%B8%BB%E8%A6%81%E4%B8%9A%E7%BB%A9%E9%A9%B1%E5%8A%A8%E5%9B%A0%E7%B4%A0) In H1 2025, the company's performance growth was primarily driven by a 7.22% increase in proprietary pharmaceutical product revenue, especially a 169.57% surge in innovative drug sales, which boosted high-margin business, while Vitamin B5 series products maintained market leadership despite industry competition - In the pharmaceutical preparation business, proprietary (including imported) pharmaceutical operating revenue increased by **7.22%** year-on-year, and innovative drug sales revenue grew by **169.57%**, serving as the core driver for a significant increase in the company's non-recurring net profit margin[38](index=38&type=chunk) - Although **Vitamin B5 series products** were affected by industry competition, leading to declines in average transaction prices and sales volumes, the company maintained its **market-leading position** through cost reduction, efficiency improvement, and strengthened management[38](index=38&type=chunk) [Analysis of Core Competitiveness](index=15&type=section&id=%E4%BA%8C%E3%80%81%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competitiveness remained unchanged during the reporting period, with specific details available in the 2024 Annual Report - The company's core competitiveness remained unchanged during the reporting period, as detailed in the **2024 Annual Report**[39](index=39&type=chunk) [Analysis of Main Business](index=15&type=section&id=%E4%B8%89%E3%80%81%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) In H1 2025, the company achieved operating revenue of RMB 2.635 billion, a 0.11% increase, and net profit attributable to shareholders of RMB 304 million, up 19.91%; pharmaceutical-related revenue accounted for 85.53% of total revenue, with innovative drugs Yilishu® and Yinikang® sales growing by 169.57%, alongside significant progress in biologics commercialization, global operations, BD collaborations, high-quality R&D, and synthetic biology new product development 2025 Semi-Annual Key Financial Indicators | Metric | Amount (RMB 10,000) | YoY Change | | :--- | :--- | :--- | | Operating Revenue | 263,511.01 | 0.11% | | Net Profit Attributable to Shareholders of Listed Company | 30,365.11 | 19.91% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items) | 23,721.00 | 32.21% | - Pharmaceutical-related operating revenue was **RMB 2,253,705,400** (RMB 225,370.54 ten thousand), accounting for **85.53%** of the company's total operating revenue; combined sales revenue of innovative drugs **Yilishu® and Yinikang®** increased by **169.57%** year-on-year[41](index=41&type=chunk) [Advancing Yilishu Commercialization and Biologics Ecosystem Development](index=16&type=subsection&id=1%E3%80%81%E6%8E%A8%E8%BF%9B%E4%BA%BF%E7%AB%8B%E8%88%92%E5%A4%9A%E4%B8%AA%E5%B8%82%E5%9C%BA%E5%95%86%E4%B8%9A%E5%8C%96%E5%8F%8A%E6%9E%84%E5%BB%BA%E7%94%9F%E7%89%A9%E8%8D%AF%E7%94%9F%E6%80%81%E7%B3%BB%E7%BB%9F) Yilishu® has completed its first shipment to the U.S. market and is approved for sale in 34 countries, with the company actively pursuing global commercial collaborations and advancing R&D projects like F-652 and N-3C01, while construction of the Shanghai International Innovation Center and Hefei Xinzhu Gene Recombinant Industrial Base progresses significantly - The first self-developed Class I macromolecular innovative biologic, **Yilishu®**, completed its first shipment to the U.S. market, with a market retail price of **USD 4,600 per dose**, marking its official entry into the U.S. market[42](index=42&type=chunk) - **Yilishu®** has been approved for marketing and sales in **34 countries**, including China, the U.S., EU, and Brazil, with shipments or sales realized in **5 countries**[42](index=42&type=chunk) - The **NMPA approved a supplementary application** for Yilishu® to change from 48-hour to 24-hour administration, the **EU approved self-injection**, and the Japanese partner initiated studies for shorter administration times[43](index=43&type=chunk) - The innovative drug **N-3C01 project** has largely completed preclinical research and will soon submit a clinical application, with potential indications for **bladder cancer and pan-solid tumors**[44](index=44&type=chunk) - The **Shanghai International Innovation Center project** completed civil engineering and outdoor works, the Hefei Xinzhu Gene Recombinant Industrial Base project's formulation line underwent debugging and validation, and the **1000L bulk drug production line** entered the trial production acceptance phase[45](index=45&type=chunk) [Anchoring Overseas Strategy, Consolidating Domestic and International Sales Systems](index=17&type=subsection&id=2%E3%80%81%E9%94%9A%E5%AE%9A%E5%87%BA%E6%B5%B7%E6%88%98%E7%95%A5%EF%BC%8C%E5%90%88%E5%B9%B6%E5%A2%83%E5%86%85%E5%A4%96%E9%94%80%E5%94%AE%E4%BD%93%E7%B3%BB%EF%BC%8C%E4%BB%A5%E5%85%A8%E7%90%83%E4%B8%80%E4%BD%93%E5%8C%96%E8%BF%90%E8%90%A5%E9%A9%B1%E5%8A%A8%E4%B8%9A%E7%BB%A9%E5%A2%9E%E9%95%BF) The company consolidated its domestic and international sales systems into a Global Commercial Business Unit to unify pharmaceutical market operations; overseas pharmaceutical preparation revenue increased by 6.46%, domestic pharmaceutical market revenue grew by 3.57%, and innovative drugs Yilishu® and Yinikang® sales surged by 169.57% - The company merged its domestic and international sales systems, establishing a **Global Commercial Business Unit** to coordinate business development, product marketing, market planning, sales strategies, and operations for both domestic and international pharmaceutical markets[46](index=46&type=chunk) - Overseas pharmaceutical preparations achieved operating revenue of **RMB 331,988,900** (RMB 33,198.89 ten thousand), a year-on-year increase of **6.46%**[47](index=47&type=chunk) - Domestic pharmaceutical market achieved operating revenue of **RMB 1,921,716,500** (RMB 192,171.65 ten thousand), a year-on-year increase of **3.57%**, with proprietary (including imported) pharmaceuticals achieving operating revenue of **RMB 1,768,848,900** (RMB 176,884.89 ten thousand), a year-on-year increase of **7.20%**[48](index=48&type=chunk) - Combined sales revenue of the two innovative drugs, **Yilishu® and Yinikang®**, increased by **169.57%** year-on-year, showing an accelerating volume trend[48](index=48&type=chunk) [Integrating Dispersed Resources, Launching Global BD Center](index=17&type=subsection&id=3%E3%80%81%E6%95%B4%E5%90%88%E5%88%86%E6%95%A3%E8%B5%84%E6%BA%90%EF%BC%8C%E5%8A%A9%E5%8A%9B%E5%85%A8%E7%90%83%20BD%20%E4%B8%AD%E5%BF%83%E5%90%AF%E8%88%AA) The company established a Global BD Center to coordinate product transactions, cross-border negotiations, alliance management, and ecosystem building, strengthening external collaborations; during the reporting period, it signed multiple cooperation agreements in Europe, Malaysia, India, and with Bayer China, and licensed oxytocin nasal spray commercialization in Russia - The company established a **Global BD Center**, responsible for transaction execution and cross-border negotiations, alliance management and ecosystem building, internationalization, and regional market expansion for products across various business units[50](index=50&type=chunk) - On the inbound side, cooperation agreements were signed with **Phar OS (Europe), Novugen (Malaysia), and Mankind (India)**, and an exclusive market promotion right for **Bayer's Xofigo® and Nexavar®** in mainland China was secured with Bayer China[51](index=51&type=chunk) - On the outbound side, a cooperation agreement was signed with **Sygardis Rus, LLC (Russia)**, authorizing them to commercialize oxytocin nasal spray in the Russian market[51](index=51&type=chunk) [Promoting High-Quality R&D and Production, Supporting Company Transformation and Upgrading](index=18&type=subsection&id=4%E3%80%81%E6%8E%A8%E8%BF%9B%E7%A0%94%E4%BA%A7%E9%AB%98%E8%B4%A8%E9%87%8F%E5%8F%91%E5%B1%95%EF%BC%8C%E5%8A%A9%E5%8A%9B%E5%85%AC%E5%8F%B8%E8%BD%AC%E5%9E%8B%E5%8D%87%E7%BA%A7) The small molecule (traditional Chinese medicine) business unit focuses on high-barrier areas like solid tumors, hematologic tumors, and rare diseases, obtaining four chemical drug registration certificates and submitting two formulation product registration applications; progress was made in traditional Chinese medicine new drug research, and internationalization achieved breakthroughs with Amikacin Sulfate Injection shipped to Italy - Domestic pharmaceutical R&D (chemical drugs) obtained **4 product registration certificates**, including Etazocine Hydrobromide Injection, and submitted **2 formulation product registration applications**, including Bilastine Oral Solution[52](index=52&type=chunk) - The statistical report for the Phase Ib patient study of the Class 1.1 traditional Chinese medicine new drug **Duanjin Jiedu Capsule** was completed; enrollment and follow-up for the Phase III clinical trial of Compound Yinhua Jiedu Granules for pediatric influenza were completed[53](index=53&type=chunk)[54](index=54&type=chunk) - The ethics approval for the lead unit of the IIT clinical study of **Compound Huangdai Tablets** for treating advanced recurrent platinum-resistant ovarian cancer patients was obtained, marking a crucial step towards treating ovarian cancer[54](index=54&type=chunk) - Breakthrough progress was made in internationalization, with **Amikacin Sulfate Injection** successfully shipped to the Italian market, and **Norepinephrine Bitartrate Injection** completing its PIC/S certification on-site inspection[55](index=55&type=chunk) [Synthetic Biology Sector: Significant Progress in New Product R&D and Construction, B5 Series Products Maintain Leading Edge](index=19&type=subsection&id=5%E3%80%81%E5%90%88%E6%88%90%E7%94%9F%E7%89%A9%E6%9D%BF%E5%9D%97%EF%BC%8C%E6%96%B0%E4%BA%A7%E5%93%81%E7%A0%94%E5%8F%91%E5%BB%BA%E8%AE%BE%E8%BF%9B%E5%B1%95%E6%98%BE%E8%91%97%EF%BC%8CB5%20%E7%B3%BB%E5%88%97%E4%BA%A7%E5%93%81%E7%BB%A7%E7%BB%AD%E4%BF%9D%E6%8C%81%E9%A2%86%E5%85%88%E4%BC%98%E5%8A%BF) The synthetic biology business unit increased investment in new product development, with Human Milk Oligosaccharide (HMO) 2'-FL obtaining FDA GRAS certification and 6'-SL obtaining Self-GRAS certification; Vitamin B5 series products maintained market leadership despite industry competition, and construction of the Hangzhou Synthetic Biology Industrial Park Phase I is accelerating - Human Milk Oligosaccharide (HMO) **2'-FL obtained FDA GRAS safety certification**, and **6'-SL obtained Self-GRAS certification**, with registration efforts in other regions progressing concurrently[56](index=56&type=chunk) - Although **Vitamin B5 series products** were affected by industry competition, leading to declines in average transaction prices and sales volumes, they still maintained a **market-leading position**[56](index=56&type=chunk) - Construction and equipment installation for the four buildings of the **Hangzhou Synthetic Biology Industrial Park Phase I project** are accelerating[56](index=56&type=chunk) Operating Revenue Composition (by Industry) | Industry | Current Period Amount (RMB) | Share of Operating Revenue | Prior Period Amount (RMB) | Share of Operating Revenue | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | | Pharmaceutical | 2,253,705,361.70 | 85.53% | 2,167,257,866.51 | 82.34% | 3.99% | | Vitamin | 302,225,793.57 | 11.47% | 375,941,164.06 | 14.28% | -19.61% | | Polymer Materials | 79,178,927.91 | 3.00% | 88,890,752.78 | 3.38% | -10.93% | Operating Revenue Composition (by Product) | Product | Current Period Amount (RMB) | Share of Operating Revenue | Prior Period Amount (RMB) | Share of Operating Revenue | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | | Proprietary Pharmaceutical Products (incl. imported) | 1,990,001,955.45 | 75.52% | 1,856,050,098.60 | 70.52% | 7.22% | | Other Pharmaceutical Products | 250,904,572.83 | 9.52% | 242,788,226.46 | 9.22% | 3.34% | | Pharmaceutical Services | 12,798,833.42 | 0.49% | 68,419,541.45 | 2.60% | -81.29% | | Vitamin | 302,225,793.57 | 11.47% | 375,941,164.06 | 14.28% | -19.61% | | Polymer Materials | 79,178,927.91 | 3.00% | 88,890,752.78 | 3.38% | -10.93% | Operating Revenue Composition (by Region) | Region | Current Period Amount (RMB) | Share of Operating Revenue | Prior Period Amount (RMB) | Share of Operating Revenue | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | | Domestic | 2,075,408,442.12 | 78.76% | 2,025,625,964.71 | 76.96% | 2.46% | | Overseas | 559,701,641.06 | 21.24% | 606,463,818.64 | 23.04% | -7.71% | [Analysis of Non-Core Business](index=21&type=section&id=%E5%9B%9B%E3%80%81%E9%9D%9E%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) The company's non-core business impacted total profit, primarily through investment income (associate losses), fair value changes (foreign exchange derivatives revaluation), asset impairment (inventories and intangible assets), non-operating income (litigation compensation), non-operating expenses (fixed asset disposals), and credit impairment (receivables bad debt provisions), none of which are sustainable Impact of Non-Core Business on Total Profit | Item | Amount (RMB) | Share of Total Profit | Reason for Formation | Sustainable | | :--- | :--- | :--- | :--- | :--- | | Investment Income | -14,370,446.64 | -4.17% | Primarily investment losses recognized from associate losses during the reporting period. | No | | Fair Value Change Gains/Losses | -459,827.92 | -0.13% | Due to revaluation of foreign exchange derivatives at period-end. | No | | Asset Impairment | -11,333,286.25 | -3.29% | Due to impairment losses on inventories and intangible assets recognized during the reporting period. | No | | Non-Operating Income | 2,571,952.61 | 0.75% | Primarily litigation compensation received during the reporting period. | No | | Non-Operating Expenses | 1,193,751.91 | 0.35% | Primarily losses from fixed asset disposals and compensation payments during the reporting period. | No | | Credit Impairment | -23,146,737.30 | -6.72% | Primarily bad debt provisions for receivables recognized based on aging portfolio during the reporting period. | No | | Other Income | 69,741,135.46 | 20.25% | Primarily income-related government grants received during the reporting period. | No | | Asset Disposal Gains | 3,858,234.66 | 1.12% | Primarily net gains from disposal of intangible assets during the reporting period. | No | [Analysis of Assets and Liabilities](index=21&type=section&id=%E4%BA%94%E3%80%81%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) At period-end, total assets were RMB 12.674 billion, up 3.16% from year-end, with construction in progress significantly increasing by 2.43% due to investments in industrial parks and innovation centers; long-term borrowings increased by 0.80%, while non-current liabilities due within one year decreased by 1.48%, and overseas assets constituted 45.67% of net assets Significant Changes in Asset Composition | Item | Current Period-end Amount (RMB) | Share of Total Assets | Prior Year-end Amount (RMB) | Share of Total Assets | Change in Share | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Total Assets | 12,674,139,895.70 | 100% | 12,285,788,088.75 | 100% | 3.16% | | | Construction in Progress | 1,140,989,321.45 | 9.00% | 807,153,241.00 | 6.57% | 2.43% | Due to increased investment in the Vitamin Industrial Park, Gene Recombinant Biopharmaceutical Base Project, and International Innovation Center Project during the reporting period. | | Long-term Borrowings | 747,170,028.46 | 5.90% | 627,163,153.57 | 5.10% | 0.80% | Primarily due to changes in loan structure, new project borrowings, and reclassification to non-current liabilities due within one year during the reporting period. | | Non-current Liabilities Due Within One Year | 389,190,380.76 | 3.07% | 558,892,484.59 | 4.55% | -1.48% | Primarily due to reduced reclassification of long-term borrowings to non-current liabilities due within one year during the reporting period. | - Total overseas assets amounted to **RMB 5,745,898,863.19**, accounting for **45.67%** of the company's net assets, primarily including assets of subsidiaries such as Hong Kong Yifan, Yifan International, and Yiyi Bio[69](index=69&type=chunk) - The company's financial assets measured at fair value totaled **RMB 85,371,843.49** at period-end, mainly comprising other debt investments and other equity instrument investments; financial liabilities totaled **RMB 459,827.92** at period-end, primarily trading financial liabilities (revaluation of foreign exchange derivatives)[71](index=71&type=chunk) [Analysis of Investment Status](index=23&type=section

证券代码：002019 证券简称：亿帆医药 公告编号：2025-044 亿帆医药股份有限公司 第八届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《2025年半年度报告摘要》及《2025年半年度报告》。 （二）会议以8票同意、0票反对、0票弃权的结果，审议通过了《关于修订 <公司章程>的议案》 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的《< 公司章程>修正案（2025 年 8 月修订）》及全文。 （三）审议通过了《关于董事会换届选举非独立董事的议案》 鉴于公司第八届董事会董事任期已届满，根据《公司法》《公司章程》和《董 事会议事规则》等有关规定，并经公司董事会提名委员会审核，公司第八届董事 会同意提名程先锋先生、林行先生、冯德崎先生为公司第九届董事会非独立董事 候选人。表决情况如下： 3.1、提名程先锋先生为公司第九届董事会非独立董事候选人； 表决结果：8 票同意、0 ...